Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Fernández Rodríguez, Juana ^a   Quiles, Francisco ^a   Blanco, Ignacio ^a   Teulé, Alex ^a   Feliubadaló, Lídia ^a   Valle, Jesús D ^a   Salinas, Mónica ^a   Izquierdo, Àngel ^b   Darder, Esther ^b   Schindler, Detlev ^c   Capellá, Gabriel ^a   Brunet, Joan ^b   Lázaro, Conxi ^a   Pujana, Miguel A ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; SCAFFOLD PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EXON; FAMILIAL CANCER; FANCP GENE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PROTEIN FUNCTION; SLX4 GENE; SPAIN;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FAMILY; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INTRONS; MALE; MUTATION, MISSENSE; RECOMBINASES;

EID: 84859109508     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-84     Document Type: Article

References (34)

1. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
2. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 2010, 362:1909-1919. 10.1056/NEJMra0809889, 3069698, 20484397.
3. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609. 10.1126/science.1073834, 12065746.
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
5. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622.
6. Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005, 37:931-933. 10.1038/ng1624, 16116424.
7. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005, 37:934-935. 10.1038/ng1625, 16116423.
8. Litman R, Peng M, Jin Z, Zhang F, Zhang J, Powell S, Andreassen PR, Cantor SB. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005, 8:255-265. 10.1016/j.ccr.2005.08.004, 16153896.
9. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319. 10.1038/nature05609, 17287723.
10. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164. 10.1038/ng1947, 17200671.
11. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668.
12. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010, 42:410-414. 10.1038/ng.569, 20400964.
13. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010, 42:406-409. 10.1038/ng.570, 20400963.
14. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 2011, 20:3278-3288. 10.1093/hmg/ddr229, 21616938.
15. Roberts TM, Kobor MS, Bastin-Shanower SA, Ii M, Horte SA, Gin JW, Emili A, Rine J, Brill SJ, Brown GW. Slx4 regulates DNA damage checkpoint-dependent phosphorylation of the BRCT domain protein Rtt107/Esc4. Mol Biol Cell 2006, 17:539-548. 1345688, 16267268.
16. Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, Harper JW. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009, 138:63-77. 10.1016/j.cell.2009.06.030, 2720686, 19596235.
17. Fekairi S, Scaglione S, Chahwan C, Taylor ER, Tissier A, Coulon S, Dong MQ, Ruse C, Yates JR, Russell P, et al. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 2009, 138:78-89. 10.1016/j.cell.2009.06.029, 2861413, 19596236.
18. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, Oostra AB, Eirich K, Korthof ET, Nieuwint AW, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011, 43:138-141. 10.1038/ng.751, 21240277.
19. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011, 43:142-146. 10.1038/ng.750, 21240275.
20. Landwehr R, Bogdanova NV, Antonenkova N, Meyer A, Bremer M, Park-Simon TW, Hillemanns P, Karstens JH, Schindler D, Dork T. Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. Breast Cancer Res Treat 2011, 130:1021-1028. 10.1007/s10549-011-1681-1, 21805310.
21. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002, 94:844-851. 10.1093/jnci/94.11.844, 12048272.
22. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL) 6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003, 63:3560-3566.
23. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001, 29:308-311. 10.1093/nar/29.1.308, 29783, 11125122.
24. Consortium GP. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073. 10.1038/nature09534, 3042601, 20981092.
25. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol 1997, 4:311-323. 10.1089/cmb.1997.4.311, 9278062.
26. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249. 10.1038/nmeth0410-248, 2855889, 20354512.
27. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081. 10.1038/nprot.2009.86, 19561590.
28. González-Pérez A, Lopez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 2011, 88:440-449. 10.1016/j.ajhg.2011.03.004, 3071923, 21457909.
29. Betts MJ, Russell RB. Amino acid properties and consequences of subsitutions. Bioinformatics for Geneticists 2003, 289-316. Chichester: John Wiley and Sons, Barnes MR, Gray IC.
30. Mohrenweiser HW, Wilson DM, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003, 526:93-125. 10.1016/S0027-5107(03)00049-6, 12714187.
31. Cantin GT, Yi W, Lu B, Park SK, Xu T, Lee JD, Yates JR. Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 2008, 7:1346-1351. 10.1021/pr0705441, 18220336.
32. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 2008, 105:10762-10767. 10.1073/pnas.0805139105, 2504835, 18669648.
33. Crossan GP, van der Weyden L, Rosado IV, Langevin F, Gaillard PH, McIntyre RE, Gallagher F, Kettunen MI, Lewis DY, Brindle K, et al. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet 2011, 43:147-152. 10.1038/ng.752, 21240276.
34. Wechsler T, Newman S, West SC. Aberrant chromosome morphology in human cells defective for Holliday junction resolution. Nature 2011, 471:642-646. 10.1038/nature09790, 21399624.